<DOC>
	<DOCNO>NCT00371410</DOCNO>
	<brief_summary>Macular edema constitutes primary cause visual impairment diabetic patient disease duration 20 year . Intravitreal triamcinolone ( IVTA ) macular focal laser photocoagulation report generate favorable result treatment diabetic macular edema , patient diffuse diabetic macular edema refractory treatment modality . The present study test safety efficacy combine treatment vitrectomy , IVTA macular focal laser photocoagulation treatment intractable diffuse diabetic macular edema .</brief_summary>
	<brief_title>Sequentially Combined Vitrectomy , IVTA Macular Focal Laser Photocoagulation Diabetic Macular Edema</brief_title>
	<detailed_description>Fifty eye 50 diabetic patient include , diagnose intractable diffuse diabetic macular edema ( DME ) . Intractable diffuse DME define biomicroscopically , angiographically tomographically proven diffuse DME , respond recur previous intravitreal triamcinolone acetonide ( IVTA ) and/or macular focal laser photocoagulation . The central macular thickness ( CMT ) great 250 μm . Preoperative ocular examination include best correct visual acuity ( BCVA ) use ETDRS chart , applanation tonometry , slit-lamp biomicroscopy , dilate fundus examination , optical coherence tomography ( OCT ) fluorescein angiography . Pars plana vitrectomy removal retinal internal limiting membrane ( ILM ) perform 50 subject eye . On day vitrectomy , triamcinolone acetonide ( 0.1 mL , 40 mg/mL ) inject intravitreally . Macular focal laser photocoagulation perform 2 week vitrectomy . As main outcome measure , BCVA record CMT measure use OCT independent observer subject 3 6 month laser photocoagulation .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>clinical diagnosis diabetes mellitus intractable diffuse DME ( diffuse DME respond recur previous IVTA and/or macular focal laser photocoagulation ) central macular thickness ( CMT ) great 250 μm presence vitreomacular traction prior history treatment DME within 3 month vitreoretinal surgery</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Vitrectomy</keyword>
	<keyword>Intravitreal triamcinolone acetonide</keyword>
	<keyword>Macular focal laser photocoagulation</keyword>
	<keyword>Best-corrected visual acuity</keyword>
	<keyword>Central macular thickness</keyword>
</DOC>